Thanks LED for pointing out the importance of CRP (inflammation biomarker) as a proxy for treatment effect in both class II and class III. Good to know Rex-L was also highly significant for class III with high CRP (thanks for correcting). That makes me smile even more.
How nice would it be (hopefully one day in the not too distant future) that Rex-L essentially eliminates PROGRESSION to class III and therefore class IV CHF for all new patients. What a significant impact on patients Quality of Life, Mortality and savings to the health system. Becoming more of a reality than a pipe dream thanks to our good friend MESOBLAST!
Cell Therapy News/Articles, page-12060
-
- There are more pages in this discussion • 5,963 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
-0.045(4.52%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 94.5¢ | $2.669M | 2.769M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2053 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.5¢ | 13191 | 2 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |